1. Medtech Insight
  2. >>Device Area
  3. >>Diabetic Care

Dexcom Promotes CGM As First-Line Tool In Type 2 Diabetes

Company Combines Education, Advocacy And Clinical Studies To Shift Standard Of Treatment.

 
• By Shubham Singh

Only 14% of people with type 2 diabetes use continuous glucose monitors, although 93% of users report a positive impact on their health. Dexcom is ramping up efforts to close this adoption gap.

One of the most significant is the Steno2Tech study, a 12-month, single-center, randomized controlled trial conducted at the Steno Diabetes Center, Copenhagen, Denmark
Key Takeaways
  • Dexcom’s multiple clinical studies, include pivotal Steno2Tech trial, to position CGM as a first-line tool in type 2 diabetes. 

      Dexcom is ramping up efforts to increase adoption of continuous glucose monitoring (CGM) among people with type 2 diabetes through...

      Read the full article – start your free trial today!

      Join thousands of industry professionals who rely on Medtech Insight for daily insights

      • Start your 7-day free trial
      • Explore trusted news, analysis, and insights
      • Access comprehensive global coverage
      • Enjoy instant access – no credit card required
      Start Free Trial

      Already a subscriber?

      More from Diabetic Care

      Medtronic To Spin Out Diabetes Unit As New Products Solidify Turn-Around Story

       
      • By Shubham Singh

      Medtronic’s diabetes spin-out – a process likely to run up to 18 months and involve 20% IPO followed by a split-off for Medtronic shareholders – will allow firm to focus on higher-margin devices.

      Abbott’s FreeStyle Libre CGM Reduces Cardiovascular Disease-Related Hospitalization

       
      • By Natasha Barrow

      The REFLECT studies showed a 78% reduction in cardiovascular disease-related hospitalization for people living with type 1 diabetes with prior low blood sugar episodes.

      Roche To Localize CGM Manufacturing in US with $550M Indiana Site Investment

       
      • By Shubham Singh

      Roche’s Indianapolis site currently produces 5.2 billion Accu-Chek test strips annually and supports distribution to 53 countries. The new CGM line will add to an already diversified operational footprint, which includes R&D, laboratories, manufacturing, and IT services.

      Consumer Healthtech Investment Totaled $4.5BN In 2024, But Bar Is High Amid Economic Uncertainty

       
      • By Marion Webb

      Global investment in consumer healthtech increased by 9% year-over-year in 2024, totaling $4.5bn, with significant interest in mental health solutions, according to Galen Growth. While the first quarter of 2025 saw raised confidence and investments, the Trump administration’s new tariffs and sweeping changes to healthcare have introduced new uncertainties.

      More from Medtech Insight

      HistoSonics’ Edison System Gains Limited UK Access, While Awaiting CE Marking

       
      • By Shubham Singh

      While HistoSonics is awaiting the CE mark in Europe, it hit a major milestone by securing early limited market access in Great Britain under a Unmet Clinical Need Authorization (UCNA), bringing its noninvasive histotripsy treatment to patients with liver tumors.

      Medtech Giants Brace for Tariffs Impact: Responses Range From Financial To Philosophical

       
      • By Marion Webb, Shubham Singh, and Nancy Pham

      Manufacturing shifts, financial planning, and supply chain changes are among the adjustments that medtech leaders are making to Trump-era tariffs. Medtech Insight’s review of first-quarter earnings calls reveals how firms are navigating the impact and uncertainty of evolving trade policies.

      Global Medtech Guidance Tracker: May 2025

       
      • By Vibha Sharma

      Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Thirty-six documents have been posted on the tracker since its last update.